fda approves first oral glp-1 obesity drug august 1 2025 FDA Approved: Orforglipron (Foundayo) — Oral GLP-1 Drug • FDA approved for chronic weight management • Indicated for obesity and overweight with comorbidities • Oral, once-daily GLP-1 receptor agonist • First non-peptide

RetatrutideA Game Changer in Obesity Pharmacotherapy First Generic GLP 1 for Weight Loss is Here Glp 1 receptor agonist hi res stock photography and images Alamy Medicaid Coverage of and Spending on GLP 1s KFF As use of GLP 1 receptor agonists (RAs) continues to rise exponentially, awareness of its most common side effects, such as nausea and vomiting, is growing. But the drugs come with some lesser known Pentagon Drops Coverage of GLP 1 Weight Loss Meds for Medicare Eligible Retirees